ST6GAL1 endows resistance of cancer cells to gefitinib (EGFR inhibitor) and trastuzumab (anti-ErbB2 antibody) (25) and also confers tumor cell resistance against hypoxia via enhancing hypoxia-inducible factor-1α (HIF-1α) expression (50). Here, ERBB2 is linked to neoplasm.